Precigen, Inc. (PGEN) Insider Trading Activity

NASDAQ$3.32
Market Cap
$997.42M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
253 of 883
Rank in Industry
141 of 506

PGEN Insider Trading Activity

PGEN Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$235,938
7
39
Sells
$54,394,221
11
61

Related Transactions

AGEE NANCY Hdirector
3
$167,643
0
$0
$167,643
Thomasian Harry Jr.Chief Financial Officer
2
$40,016
0
$0
$40,016
Tennant PhilChief Commercial Officer
1
$21,480
0
$0
$21,480
Shah Rutul RChief Operating Officer
1
$6,800
0
$0
$6,800
KINDLER JEFFREY Bdirector
0
$0
3
$1.46M
$-1.46M
KIRK RANDAL J
0
$0
8
$52.93M
$-52.93M

About Precigen, Inc.

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

Insider Activity of Precigen, Inc.

Over the last 12 months, insiders at Precigen, Inc. have bought $235,938 and sold $54.39M worth of Precigen, Inc. stock.

On average, over the past 5 years, insiders at Precigen, Inc. have bought $9.37M and sold $24.99M worth of stock each year.

Highest buying activity among insiders over the last 12 months: AGEE NANCY H (director) — $167,643. Thomasian Harry Jr. (Chief Financial Officer) — $40,016. Tennant Phil (Chief Commercial Officer) — $21,480.

The last purchase of 6,000 shares for transaction amount of $21,480 was made by Tennant Phil (Chief Commercial Officer) on 2025‑09‑29.

List of Insider Buy and Sell Transactions, Precigen, Inc.

2025-12-22SaleKIRK RANDAL J
1.88M
0.5985%
$4.18
$7.88M
+1.20%
2025-12-22SaleKIRK RANDAL J
1.9M
0.6036%
$4.18
$7.94M
+1.20%
2025-12-12SaleKINDLER JEFFREY Bdirector
235,467
0.0769%
$3.63
$855,899
+19.24%
2025-11-21SaleKIRK RANDAL J
937,308
0.308%
$3.83
$3.59M
+7.86%
2025-11-20SaleKIRK RANDAL J
942,832
0.3283%
$4.08
$3.85M
+7.18%
2025-11-19SaleKIRK RANDAL J
1.09M
0.383%
$4.47
$4.86M
-0.95%
2025-09-30SaleKIRK RANDAL J
1.81M
0.6309%
$3.41
$6.17M
+23.56%
2025-09-30SaleKINDLER JEFFREY Bdirector
106,837
0.0369%
$3.38
$361,109
+23.56%
2025-09-29SaleKINDLER JEFFREY Bdirector
67,523
0.0225%
$3.60
$243,083
+11.85%
2025-09-29PurchaseTennant PhilChief Commercial Officer
6,000
0.002%
$3.58
$21,480
+11.85%
2025-09-26PurchaseThomasian Harry Jr.Chief Financial Officer
2,932
0.001%
$3.42
$10,027
+15.53%
2025-09-26PurchaseShah Rutul RChief Operating Officer
2,000
0.0007%
$3.40
$6,800
+15.53%
2025-09-25PurchaseThomasian Harry Jr.Chief Financial Officer
8,284
0.0026%
$3.62
$29,988
+16.05%
2025-09-19SaleKIRK RANDAL J
3.6M
1.1874%
$3.68
$13.24M
+7.47%
2025-09-18SaleKIRK RANDAL J
1.4M
0.4784%
$3.86
$5.42M
+5.92%
2025-09-04PurchaseAGEE NANCY Hdirector
15,000
0.0051%
$4.60
$69,000
-11.73%
2025-08-28PurchaseAGEE NANCY Hdirector
10,645
0.0037%
$4.65
$49,491
-11.15%
2025-08-19PurchaseAGEE NANCY Hdirector
15,360
0.0051%
$3.20
$49,152
+25.78%
2024-08-09PurchaseKIRK RANDAL J
23.53M
7.203%
$0.85
$20M
+20.91%
2024-08-09PurchasePerez Jeffrey ThomasSVP, IP Affairs
58,823
0.018%
$0.85
$50,000
+20.91%
Total: 314
*Gray background shows transactions not older than one year

Insider Historical Profitability

3.55%
Thomasian Harry Jr.Chief Financial Officer
468626
0.156%
$1.56M55
<0.0001%
Shah Rutul RChief Operating Officer
405959
0.1351%
$1.35M24
<0.0001%
KIRK RANDAL J
341189
0.1136%
$1.13M7020
+6.88%
AGEE NANCY Hdirector
217841
0.0725%
$723,232.1230
KINDLER JEFFREY Bdirector
110603
0.0368%
$367,201.9625
<0.0001%
Tennant PhilChief Commercial Officer
65031
0.0216%
$215,902.9210
Ares Trading S.A.10 percent owner
20647152
6.8726%
$68.55M167
+52.74%
Sabzevari HelenPresident and CEO
1560004
0.5193%
$5.18M123
<0.0001%
Frank Stevendirector
882358
0.2937%
$2.93M10
<0.0001%
Hassan Freddirector
878942
0.2926%
$2.92M20
<0.0001%
Perez Jeffrey ThomasSVP, IP Affairs
743097
0.2473%
$2.47M320
<0.0001%
Lehr Donald P.Chief Legal Officer
428916
0.1428%
$1.42M221
+21.62%
MITCHELL DEAN Jdirector
356836
0.1188%
$1.18M20
<0.0001%
Sterling Rick L.Chief Financial Officer
340020
0.1132%
$1.13M013
Reed Thomas D.Chief Science Officer
148888
0.0496%
$494,308.1629
+21.52%
Frost Gregory IanSVP--Health Sector
100000
0.0333%
$332,000.0030
<0.0001%
LIFFMAN JOEL DSVP, Finance
85541
0.0285%
$283,996.1212
<0.0001%
SHAPIRO ROBERT Bdirector
82966
0.0276%
$275,447.1220
<0.0001%
Bostick ThomasChief Operating Officer
74280
0.0247%
$246,609.6005
Krishnan Krish SChief Operating Officer
42000
0.014%
$139,440.0012
+59.01%
Krishnan SumaSVP--Product Development
42000
0.014%
$139,440.0012
+59.01%
Walsh Robert F. IIISVP, Energy & Fine Chem.
28816
0.0096%
$95,669.1202
Kasser Thomas R.SVP--Food Sector
15000
0.005%
$49,800.0020
+19.61%
Nimrodi NirChief Business Officer
5708
0.0019%
$18,950.5621
<0.0001%
Last Andrew J.Chief Operating Officer
4000
0.0013%
$13,280.0020
+0.56%
Huang KellySVP-Consumer Sector
3200
0.0011%
$10,624.0010
+59.01%
Gupta Vinita Ddirector
3000
0.001%
$9,960.0010
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

Precigen, Inc.
(PGEN)
$607,159,124
92
3.55%
$997.42M
$14,874,415
78
37.43%
$1.07B
$61,783,526
37
18.57%
$964.02M
$35,092,436
31
38.62%
$959.26M
$150,336,897
29
-5.97%
$1.05B
$105,195,330
29
14.02%
$1.05B
$21,945,105
15
-26.51%
$1.09B
$48,220,484
14
2.13%
$1.01B
$133,809,976
13
31.29%
$873.45M
$49,967,154
11
62.08%
$1.15B
$1,435,760
10
2.01%
$976.68M
$5,794,001
10
23.26%
$975.36M
$1,580,951
9
-14.18%
$957.71M
$38,624,786
9
1.26%
$929.86M
$21,792,890
6
75.72%
$895.57M
$1,944,616
6
0.35%
$1.06B
$41,260,462
6
-1.36%
$1B
$33,624,000
2
-50.37%
$1.01B
$504,640
1
16.84%
$898.53M

PGEN Institutional Investors: Active Positions

Increased Positions114+79.72%47M+42.1%
Decreased Positions56-39.16%21M-19.22%
New Positions38New6MNew
Sold Out Positions20Sold Out4MSold Out
Total Postitions201+40.56%137M+22.88%

PGEN Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Patient Capital Management, Llc$113,252.007.48%26.46M+10M+62.65%2025-09-30
Tang Capital Management Llc$53,072.003.5%12.4M+12MNew2025-09-30
Blackrock, Inc.$52,002.003.43%12.15M+1M+9.01%2025-09-30
Vanguard Group Inc$38,273.002.53%8.94M-127,744-1.41%2025-09-30
State Street Corp$19,216.001.27%4.49M+1M+48.22%2025-09-30
Geode Capital Management, Llc$16,473.001.09%3.85M+99,556+2.65%2025-09-30
Iridian Asset Management Llc/Ct$15,695.001.04%3.67M-611,716-14.3%2025-09-30
Point72 Asset Management, L.P.$11,732.000.77%2.74M+3MNew2025-09-30
Occam Crest Management Lp$11,545.000.76%2.7M+3MNew2025-09-30
Citadel Advisors Llc$11,538.000.76%2.7M+2M+756.35%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.